鮑曼不動(dòng)桿菌感染因廣泛的抗菌藥耐藥性和高死亡率而備受關(guān)注,常規(guī)抗菌藥治療策略的療效欠佳。鮑曼不動(dòng)桿菌和機(jī)體免疫反應(yīng)的相互作用影響感染的嚴(yán)重程度以及臨床轉(zhuǎn)歸,通過(guò)免疫調(diào)節(jié)改善機(jī)體免疫反應(yīng)是有效的治療方案。免疫調(diào)節(jié)劑具有單獨(dú)治療或作為免疫佐劑聯(lián)合抗菌藥治療鮑曼不動(dòng)桿菌感染的潛力,成為有希望改善感染結(jié)局的策略,由此開(kāi)發(fā)的新療法引起了廣泛關(guān)注。對(duì)不同來(lái)源的(生物制劑、免疫系統(tǒng)產(chǎn)物、化學(xué)合成制劑、中藥或植物藥成分)免疫調(diào)節(jié)劑抗鮑曼不動(dòng)桿菌感染的研究進(jìn)展進(jìn)行闡述,以期對(duì)免疫治療提供幫助。

Acinetobacter baumannii infections are of great concern because of their widespread antimicrobial resistance and high mortality. Conventional antimicrobial drug treatment strategies are not sufficiently effective. The interaction between A. baumannii and the host immune response influences the severity of infection as well as clinical regression. Improving the host immune response through immunomodulation is an effective therapeutic option. Immunomodulators have the potential to treat A. baumannii infections either alone or as immune adjuvants in combination with antimicrobials. It has emerged as a promising strategy to improve infection outcomes. New therapies based on immunomodulators has attracted much attention. In this article, the research progress of different types of drugs against A. baumannii infection(such as biological agents, immune system products, chemically synthesized preparations, traditional Chinese medicine or plant medicine ingredients) were systematically described, hoping to provide help for immunotherapy of A. baumannii infection.

R979.5，R978.1

國(guó)家重點(diǎn)研發(fā)計(jì)劃項(xiàng)目(2020YFC2006000)